GlassScriptPhysician profile
Mark E Harvey
NPI 1558380907
$2,103.50
in general payments reported to CMS, 2019-2025
13 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.12 · 2020: $47.58 · 2022: $452 · 2023: $303 · 2024: $38.16 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223 · Travel and Lodging: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.16 |
| Travel and Lodging | $365.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $857.88 | 2025 | Illuccix |
| Novocure INC. | $301.75 | 2022-2024 | Optune |
| Medtronic, INC. | $161.58 | 2022 | |
| Ge Healthcare | $138.73 | 2025 | |
| Janssen Biotech, INC. | $134.52 | 2022-2023 | Carvykti, Darzalex, Tecvayli |
| Gt Medical Technologies, INC | $125.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $106.50 | 2023-2025 | |
| Teleflex LLC | $94.75 | 2025 | Barrigel |
| Merck Sharp & Dohme LLC | $50.51 | 2023-2025 | Keytruda, Keytruda Qlex |
| Blue Earth Diagnostics | $48.90 | 2019-2025 | Posluma |
| Bayer Healthcare Pharmaceuticals INC. | $34.58 | 2020-2024 | |
| Varian Medical Systems, INC. | $26.72 | 2020 | |
| Tersera Therapeutics LLC | $22.08 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.